Characteristics, therapeutic pathway and the economic burden of patients with drug‐resistant epilepsy: A real‐world analysis following the introduction of cenobamate in Italy

This real-world study highlights a progressively earlier adoption of cenobamate in Italy over the last few years, with patients starting after fewer prior treatments. Compared to patients potentially eligible but untreated with cenobamate, those receiving cenobamate showed greater treatment persistence, reduced polypharmacy, fewer hospitalizations, and fewer neurological visits. Despite higher drug costs, overall health care efficiency improved, supporting its potential as an effective earlier-line option.